Brain Cancer

2010 Report on Cancer Statistics in Alberta
Acknowledgements

This report was made possible through Alberta Health Services, Cancer Care, Cancer Surveillance and the many contributions of staff and management across Alberta Health Services as well as external agencies and individuals.

The authors wish to thank individuals working in the following AHS departments and partner agencies for their contributions to this report: Alberta Cancer Registry, Surveillance and Health Status Assessment, Alberta Health and Statistics Canada. Contributions included provision of information, analysis and interpretation, and assistance with consultation sessions and communication of the report.

- **Report Editor:**
  Dr. Juanita Hatcher, Director, Cancer Surveillance

- **Project Coordinator:**
  Barry Obondo, Information Dissemination Coordinator

- **Analysis and Review:**
  Amy Colquhoun, Epidemiologist
  Halim Elamy, Surveillance Analyst
  Li Huang, Senior Surveillance Analyst
  Anthony Karosas, Surveillance Analyst
  Dr. Fengxiao Li, Survey Analyst
  Andrew Min, Assistant Programmer Analyst
  Chris Normandeau, Project Lead
  Tyler Pittman, Survey Analyst
  Dr. Zhenguo Qiu, Biostatistician
  Marjan Rekabdar, Surveillance Analyst
  Janine Schouten, Environmental Exposure Analyst
  Mengzhe Wang, Manager, Analytical Team
  Jing Yang, Clinical Data Analyst
  Yufei Zheng, Surveillance Analyst Practicum Student

- **Design Assistance:**
  Ashley Lakusta, Administrative Support III

**Suggested Citation:**

**For More Information:**
Visit our website: [http://www.albertahealthservices.ca/1703.asp](http://www.albertahealthservices.ca/1703.asp)
Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose of the Report</td>
<td>4</td>
</tr>
<tr>
<td>Navigating the Report</td>
<td>4</td>
</tr>
<tr>
<td>Data Notes</td>
<td>4</td>
</tr>
<tr>
<td>Summary</td>
<td>5</td>
</tr>
<tr>
<td>Probability of Developing and Dying from Prostate Cancer</td>
<td>6</td>
</tr>
<tr>
<td>Potential Years of Life Lost</td>
<td>7</td>
</tr>
<tr>
<td>Prevalence</td>
<td>8</td>
</tr>
<tr>
<td>Incidence and Mortality</td>
<td>9</td>
</tr>
<tr>
<td>Relative Survival</td>
<td>16</td>
</tr>
<tr>
<td>Further Information</td>
<td>18</td>
</tr>
<tr>
<td>References</td>
<td>19</td>
</tr>
<tr>
<td>Contact Information</td>
<td>19</td>
</tr>
</tbody>
</table>
Purpose of the Report

Cancer Surveillance is a specialized team within Alberta Health Services, Cancer Care, that actively contributes to Alberta Health Service’s goal of creating the best-performing publicly funded health system in Canada. This is accomplished by conducting cancer surveillance through the collection, integration, analysis and dissemination of cancer related data and information.

The report is designed to provide comprehensive and detailed information regarding cancer in Alberta. It will help support health professionals, researchers and policy makers in the planning, monitoring and evaluation of cancer-related health programs and initiatives. It will also be a useful education tool for the general public and media.

Navigating the Report

This document provides information on brain cancer statistics in Alberta. Details about individual cancer types are available within separate documents. The words highlighted in dark blue are terms described in detail in the Glossary within the Appendix document.

Data Notes

In this document, the term “cancer” refers to invasive cancers unless otherwise specified. It is important to note that this document contains both actual and estimated data; distinctions are made where applicable. The numbers published in this report should be considered provisional, as a few cases and deaths may be registered in subsequent years. The data in this report reflect the state of the Alberta Cancer Registry as of July 31, 2012.

For detailed descriptions about data sources and how they affect data presented in this report, please see the Appendix document.
Summary

- Approximately **1 in 121** men and **1 in 179** women will develop invasive brain cancer within their lifetime.
- In 2010, **4,462** potential years of life were lost due to brain cancer.
- As of December 31, 2010, approximately **1,150** Albertans were alive who had previously been diagnosed with brain cancer.
- From 1990 to 2010*, both **male and female** brain cancer **incidence rates have remained stable**.
- From 1990 to 2010*, both **male and female** brain cancer **mortality rates have remained stable**.
- In 2010, there were **188** new cases of brain cancer in Alberta and **178** deaths due to the disease.
- Approximately **280** cases of brain cancer are expected to be diagnosed in 2015.
- The five-year relative survival ratio for brain cancer in Alberta is approximately **28%** for those diagnosed between 2008 and 2010.

*Year range represents the period over which the most recent significant trend was observed.
Probability of Developing and Dying from Brain Cancer

The *probability of developing or dying of cancer* measures the risk of an individual in a given age range developing or dying of cancer, and is conditional on the person being brain cancer-free prior to the beginning of that age range.

It is important to note that the probabilities of developing and dying of cancer represent all of Alberta’s population on average and should be interpreted with caution at the individual level as the probabilities will be affected by the risk behaviours of the individual. In addition, someone diagnosed with cancer has a higher probability of developing another cancer in the future.¹

The probability of developing brain cancer increases with age, after an initial peak as a child, and varies by sex (*Table 13-1*). Approximately 1 in 121 males and 1 in 179 females will develop invasive brain cancer in their lifetime.

On a population basis the probability of developing brain cancer by the end of the age range for a brain cancer-free individual at the beginning of the age range are shown in the bottom eight rows of *Table 13-1*. For instance, a brain cancer-free female representative of the general population at age 40 has a 1 in 2,587 chance of developing brain cancer by the time she is 50.

The probability of dying from brain cancer increases with age, after an initial peak as a child, and varies by sex (*Table 13-2*). Approximately 1 in 143 males and 1 in 214 females will die of invasive brain cancer.

On a population basis the probability of a cancer-free individual at the beginning of the age range dying from brain cancer by the end of the age range are shown in the bottom eight rows of *Table 13-2*. For example, a cancer-free female representative of the general population at age 40 has a 1 in 4,290 chance of dying from brain cancer by the time she is 50.

---

**Table 13-1**: Probability of Developing Brain Cancer by Age and Sex, Alberta, 2006-2010

<table>
<thead>
<tr>
<th>Age Group (Years)</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lifetime Risk (all ages)</td>
<td>1 in 121</td>
<td>1 in 179</td>
</tr>
<tr>
<td>0 – 20</td>
<td>1 in 1,542</td>
<td>1 in 2,016</td>
</tr>
<tr>
<td>20 - 30</td>
<td>1 in 3,017</td>
<td>1 in 4,207</td>
</tr>
<tr>
<td>30 - 40</td>
<td>1 in 2,286</td>
<td>1 in 2,697</td>
</tr>
<tr>
<td>40 - 50</td>
<td>1 in 1,406</td>
<td>1 in 2,587</td>
</tr>
<tr>
<td>50 - 60</td>
<td>1 in 823</td>
<td>1 in 1,356</td>
</tr>
<tr>
<td>60 - 70</td>
<td>1 in 542</td>
<td>1 in 845</td>
</tr>
<tr>
<td>70 - 80</td>
<td>1 in 464</td>
<td>1 in 828</td>
</tr>
<tr>
<td>80+</td>
<td>1 in 335</td>
<td>1 in 548</td>
</tr>
</tbody>
</table>

**Data Sources**: Alberta Cancer Registry, Alberta Health

---

**Table 13-2**: Probability of Dying from Brain Cancer by Age and Sex, Alberta, 2006-2010

<table>
<thead>
<tr>
<th>Age Group (Years)</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lifetime Risk (all ages)</td>
<td>1 in 143</td>
<td>1 in 214</td>
</tr>
<tr>
<td>0 - 20</td>
<td>1 in 4,824</td>
<td>1 in 6,250</td>
</tr>
<tr>
<td>20 - 30</td>
<td>1 in 6,746</td>
<td>Less than 1 in 10,000</td>
</tr>
<tr>
<td>30 - 40</td>
<td>1 in 3,594</td>
<td>1 in 2,540</td>
</tr>
<tr>
<td>40 - 50</td>
<td>1 in 1,887</td>
<td>1 in 4,290</td>
</tr>
<tr>
<td>50 - 60</td>
<td>1 in 1,003</td>
<td>1 in 1,826</td>
</tr>
<tr>
<td>60 - 70</td>
<td>1 in 598</td>
<td>1 in 859</td>
</tr>
<tr>
<td>70 - 80</td>
<td>1 in 465</td>
<td>1 in 729</td>
</tr>
<tr>
<td>80+</td>
<td>1 in 328</td>
<td>1 in 555</td>
</tr>
</tbody>
</table>

**Data Sources**: Alberta Cancer Registry, Alberta Health
Potential Years of Life Lost

One frequently used measure of premature death is **potential years of life lost (PYLL)**. PYLL due to cancer is an estimate of the number of years that people would have lived had they not died from cancer. PYLL due to cancer has been calculated by multiplying the number of deaths in each age group and the absolute difference between the mid-point age of an age group and the age-specific life expectancy. The age-specific life expectancy is calculated by determining the age to which an individual would have been expected to live had they not died from cancer. PYLL is one way to measure the impact, or burden, of a disease on a population.

In 2010, **4,462** potential years of life were lost due to brain cancer, which constitutes about 5% of PYLL for all cancers (**Figure 13-1**).
**Prevalence**

The *prevalence* of a disease is defined as the number of people alive at a given time point who had been previously diagnosed with that disease.

Limited-duration brain cancer prevalence represents the number of people alive on a certain day who had previously been diagnosed with brain cancer within a specified time period (e.g. 2, 5, 10 or 20 years) while complete brain cancer prevalence represents the number of people alive on a certain day who had previously been diagnosed with brain cancer, regardless of how long ago the diagnosis was.²

In this section of the report, both limited-duration and complete brain cancer prevalence are presented; the latter describing the number of people alive as of December 31, 2010 who had ever been diagnosed with brain cancer.

Prevalence is a useful indicator of the impact of cancer on individuals, the healthcare system and the community as a whole. Although many cancer survivors lead healthy and productive lives, the experience can have a strong impact on the physical and emotional well-being of individuals and their families. The cancer experience can also result in the continued use of the healthcare system through rehabilitation or support services, as well as loss of work productivity that can affect the whole community.

---

**Table 13-3: Limited-Duration and Complete Prevalence for Brain Cancer, Both Sexes Combined, Alberta, 2010**

<table>
<thead>
<tr>
<th>Duration</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-Year</td>
<td>221</td>
</tr>
<tr>
<td>5-Year</td>
<td>418</td>
</tr>
<tr>
<td>10-Year</td>
<td>644</td>
</tr>
<tr>
<td>20-Year</td>
<td>886</td>
</tr>
<tr>
<td>Complete</td>
<td>1,154</td>
</tr>
</tbody>
</table>

*Data Source: Alberta Cancer Registry*

As of December 31, 2010, approximately 1,150 Albertans were alive who had previously been diagnosed with brain cancer (*Table 13-3*) out of which approximately 220 Albertans were alive on the same date who had been diagnosed with brain cancer in the previous two years, the period during which cases are more likely to receive definitive treatments.
Brain Cancer Incidence and Mortality

**Incidence counts** are the number of new cancer cases diagnosed during a specific time period in a specific population. In this section of the report, incidence counts refer to the number of new brain cancer diagnoses in Albertan residents in a calendar year. Incidence rates are the number of new brain cancer cases diagnosed per 100,000 population in a specific time period.

**Mortality counts** describe the number of deaths attributed to cancer during a specific period of time in a specific population. In this section of the report, mortality refers to the number of deaths due to brain cancer in Albertan residents in a calendar year, regardless of date of diagnosis. Mortality rates are the number of deaths per 100,000 population in a specific time period.

In order to compare cancer incidence or cancer mortality over time or between populations, **age-standardized incidence rates (ASIRs)** or **age-standardized mortality rates (ASMRs)** are presented. These are weighted averages of age-specific rates using a standard population to determine the weights. These rates are useful because they are adjusted for differences in age distributions in a population over time, which permit comparisons of cancer incidence or mortality among populations that differ in size, structure and/or time period. ASIRs and ASMRs give the overall incidence and mortality rates that would have occurred if the population of Alberta had been the same as the standard population. In this report the Canadian 1991 population is used as the standard population.

**Three-year moving averages** are used to smooth out year-to-year fluctuations so that the underlying trend may be more easily observed. They are calculated based on aggregating three years of data by age group. Age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) are presented as three-year moving averages. This smoothing of trends is especially important when the number of cancer cases per year is relatively small, where year-to-year variability can be quite large.

Incidence and mortality can be affected by a variety of factors; implementation of public health prevention or screening strategies that either prevent disease or find cancer in its early stages when treatment is generally more successful, the development of cancer treatment programs that may impact chances of survival and research innovations.

The following figures show incidence and mortality trends for brain cancer in Alberta. Separate analyses for both incidence and mortality are shown in subsequent sections. The statistical significance of the trends was determined by using Joinpoint\(^3\) method and is described in the text accompanying each graph. Joinpoint models are based on yearly rates; hence there may be slight differences in the rates presented in the text (from Joinpoint model) and the graphs (where ASIRs and ASMRs are shown as three-year moving averages).
Brain cancer ASIRs in both sexes combined have not changed significantly since 1990 (Figure 13-2). In 2010, the ASIR for brain cancer in both sexes combined was 5 per 100,000 population.

Brain cancer ASMRs in both sexes combined have not changed significantly since 1990 (Figure 13-2). In 2010, the ASMR for brain cancer in both sexes combined was 4 per 100,000 population.

Male brain cancer ASIRs have not changed significantly since 1990 (Figure 13-3). In 2010, the ASIR for brain cancer in males was 6 per 100,000 male population.

Male brain cancer ASMRs have not changed significantly since 1990 (Figure 13-3). In 2010, the ASMR for brain cancer in males was 6 per 100,000 male population.
Brain Cancer Incidence

The following three figures (Figures 13-5 to 13-7) provide information on brain cancer incidence in Alberta. The number of new cancer cases in Alberta is affected not only by changes in the incidence rates, but also by the changes in the age structure and growth of the population. In order to compare trends over time, age-standardized incidence rates (ASIRs) are also provided.

In Figures 13-5 and 13-6 observed age standardized incidence rates are shown for 1990-2009, and projected rates for 2010-2015, and observed numbers of new brain cancer cases are shown for the years 1990-2010 and projected numbers for 2011-2015.

The projected cancer numbers were calculated by applying the estimated age-specific cancer incidence rates to the projected age-specific population figures provided by Alberta Health. These were observed up to 2009 and estimated for 2010-2015. Caution should be exercised when comparing Canada and Alberta rates as Canadian rates are yearly rates while Alberta rates are three-year moving averages.

The estimated brain cancer incidence rates were calculated by extrapolating the historical trends in age-specific rate based on data for 1985-2009.

**Figure 13-4: Age-Standardized Incidence Rates (ASIRs) and Mortality Rates (ASMRs) and 95% Confidence Intervals (CI) for Brain Cancer, Females, Alberta, 1990-2010**

Data Sources: Alberta Cancer Registry, Alberta Health

Female brain cancer ASIRs have not changed significantly since 1990 (Figure 13-4). In 2010, the ASIR for brain cancer in females was 4 per 100,000 female population.

Female brain cancer mortality rates have not changed significantly since 1990 (Figure 13-4). In 2010, the ASMR for brain cancer in females was 3 per 100,000 female population.
In 2010, 113 cases of male brain cancer were diagnosed in Alberta (Figure 13-5). Alberta ASIRs for male brain cancer in Alberta were generally lower than those in Canada.

Approximately 170 cases of male brain cancer will be diagnosed in Alberta in 2015.

In 2010, 75 cases of female brain cancer were diagnosed in Alberta (Figure 13-6). Alberta ASIRs for female brain cancer were generally lower than those in Canada.

Approximately 100 females will be diagnosed with brain cancer in 2015.
Incidence rates of brain cancer increase with age for both males and females (Figure 13-7). Age-specific incidence rates incidence rates for brain cancer are somewhat elevated in those under 10 years of age, then lower after which the rates rise at about age 40. Female rates are generally lower than male rates for all ages and the oldest age groups have the highest cancer rates.

**Brain Cancer Mortality**

The following three figures (Figures 13-8 to 13-10) provide information on brain cancer mortality in Alberta. The number of deaths in Alberta is affected not only by changes in the mortality rates, but also by the changes in the age structure and growth of the population. In order to compare trends over time, age-standardized mortality rates (ASMRs) are also provided.

In Figures 13-8 and 13-9 observed age standardized mortality rates are shown for 1990-2009, and projected rates for 2010-2015, and observed numbers of cancer deaths are shown for the years 1990-2010 and projected numbers for 2011-2015.

The projected numbers of cancer deaths were calculated by applying the estimated age-specific cancer mortality rates to the age-specific population figures provided by Alberta Health. These were observed up to 2009 and estimated for 2010-2015. Caution should be exercised when comparing Canada and Alberta rates as Canadian rates are yearly rates while Alberta rates are three-year moving averages.

The estimated brain cancer mortality rates were calculated by extrapolating the historical trends in age-specific rate based on data in 1985-2009.

Data Sources: Alberta Cancer Registry, Alberta Health
**Figure 13-8:** Actual and Projected Number of Deaths and Age-Standardized Mortality Rates (ASMRs)\(^*\)\(^†\) for Brain Cancer, Males, Alberta, 1990-2015

**Figure 13-9:** Actual and Projected Number of Deaths and Age-Standardized Mortality Rates (ASMRs)\(^*\)\(^†\) for Brain Cancer, Females, Alberta, 1990-2015

Data Sources: Alberta Cancer Registry, Alberta Health, Canadian Cancer Society

In 2010, 117 males died from brain cancer in Alberta (Figure 13-8). Alberta ASMRs for male brain cancer were generally higher than those in Canada.

Approximately 130 males are expected to die from brain cancer in Alberta in 2015.

In 2010, 61 females died from brain cancer in Alberta (Figure 13-9). Alberta ASMRs for female brain cancer were similar to those in Canada.

Approximately 90 females are expected to die from brain cancer in Alberta in 2015.

---

\(^*\) Three-year moving average.

\(^†\) Standardized to 1991 Canadian population.
Male and female brain cancer mortality rates differ by age and sex (Figure 13-10). Age-specific mortality rates for male brain cancer increase rapidly after about the age of 30, whereas they begin increasing after about the age of 35 for females. Generally, female rates are lower than male rates. The highest brain cancer mortality rates occur in the older age groups.

Data Sources: Alberta Cancer Registry, Alberta Health
### Brain Cancer Survival

Cancer survival ratios indicate the proportion of people who will be alive at a given time after they have been diagnosed with cancer. Survival is an important outcome measure and is used for evaluating the effectiveness of cancer control programs. Survival depends on several factors including the cancer type (most importantly site, morphology and stage at diagnosis), sex, age at diagnosis, health status and available treatments for that cancer. While relative survival ratios (RSRs) give a general expectation of survival over the whole province, these ratios may not apply to individual cases. Individual survival outcomes depend on the stage at diagnosis, treatment and other individual circumstances.

Relative survival ratios are calculated by comparing the survival of cancer patients with that expected in the general population of Albertans of the same age, sex and in the same calendar year to obtain a crude estimate.

RSRs are estimated by the **cohort method**\(^6\) when complete follow-up data (e.g., at least five years of follow-up to estimate five-year rate) after diagnosis are available. For recently diagnosed cases, whose complete follow-up data are not available, the up-to-date estimates are computed using the **period method.**\(^7\) However, comparison between cohort and period RSRs should be interpreted with caution because of the two different methods used to derive the respective ratios.

The relative survival ratio is usually expressed as a percentage (%) and the closer the value is to 100%, the more similar the survival pattern is to the general population.

**Figure 13-11:** One, Three and Five-Year Relative Survival Ratios and 95% Confidence Intervals (CI) for Brain Cancer, Both Sexes Combined, Alberta, 1991-1993\(^3\), 1998-2000\(^\dagger\) and 2008-2010\(^\ast\)

Data Sources: Alberta Cancer Registry, Statistics Canada

The five-year relative survival ratio for individuals diagnosed with brain cancer in the period 2008-2010 is an estimated 28% indicating that out of individuals diagnosed with this cancer between 2008 and 2010, around 28% are as likely to be alive five years after diagnosis as individuals from the general population of the same age.

There has been no change in five-year relative survival ratios for individuals diagnosed with brain cancer in 2008-2010 compared to those diagnosed in 1991-1993 (Figure 13-11).
The five-year relative survival ratio for males diagnosed with brain cancer in the period 2008-2010 is an estimated 28% indicating that out of males diagnosed with this cancer between 2008 and 2010, around 28% are as likely to be alive five years after diagnosis as males from the general population of the same age.

There has been no change in five-year relative survival ratios for males diagnosed with brain cancer in 2008-2010 compared to those diagnosed in 1991-1993 (Figure 13-12).

The five-year relative survival ratio for females diagnosed with brain cancer in the period 2008-2010 is an estimated 29% indicating that out of females diagnosed with this cancer between 2008 and 2010, around 29% are as likely to be alive five years after diagnosis as females from the general population of the same age.

There has been no change in five-year relative survival ratios for females diagnosed with brain cancer in 2008-2010 compared to those diagnosed in 1991-1993 (Figure 13-13).
Further Information

Further information is available on a separate document, the Appendix:

- **Appendix 1**: Glossary
- **Appendix 2**: Cancer Definitions
- **Appendix 3**: Data Notes
References


